The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram;
Arnone, D, Wise, T, Walker, C, Cowen, PJ, Howes, O & Selvaraj, S 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol 84, pp. 152-159. DOI: 10.1016/j.pnpbp.2018.01.021

Body composition in Spinocerebellar ataxia type 3 and 10 patients: Comparative study with control group;
Leite, CDMBA, Schieferdecker, MEM, Frehner, C, Munhoz, RP, Ashizawa, T & Teive, HAG 2018, Nutritional Neuroscience, pp. 1-6. DOI: 10.1080/1028415X.2018.1469282

Sleep disorders in spinocerebellar ataxia type 10;
London, E, Camargo, CHF, Zanatta, A, Crippa, AC, Raskin, S, Munhoz, RP, Ashizawa, T & Teive, HAG 2018, Journal of Sleep Research. DOI: 10.1111/jsr.12688

Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities;
Rizzo, G, Veronese, M, Tonietto, M, Bodini, B, Stankoff, B, Wimberley, C, Lavisse, S, Bottlaender, M, Bloomfield, PS, Howes, O, Zanotti-Fregonara, P, Turkheimer, FE & Bertoldo, A 2017, Journal of Cerebral Blood Flow and Metabolism. DOI: 10.1177/0271678X17742004

Intron retention induced by microsatellite expansions as a disease biomarker;
Sznajder, LJ, Thomas, JD, Carrell, EM, Reid, T, McFarland, KN, Cleary, JD, Oliveira, R, Nutter, CA, Bhatt, K, Sobczak, K, Ashizawa, T, Thornton, CA, Ranum, LPW & Swanson, MS 2018, Proceedings of the National Academy of Sciences of the United States of America, vol 115, no. 16, pp. 4234-4239. DOI: 10.1073/pnas.1716617115

A crystal ball for survival for spinocerebellar ataxias?;
Ashizawa, T 2018, The Lancet Neurology, vol 17, no. 4, pp. 292-294. DOI: 10.1016/S1474-4422(18)30088-7

Usability and Validation of the Smarter Balance System: An Unsupervised Dynamic Balance Exercises System for Individuals With Parkinson's Disease;
Fung, A, Lai, EC & Lee, B-C 2018, IEEE Transactions on Neural Systems and Rehabilitation Engineering, vol 26, no. 4, pp. 798-806. DOI: 10.1109/TNSRE.2018.2808139

Advantages and limits of targeted radionuclide therapy with somatostatin antagonists;
Hindie, E, Morgat, C, Zanotti-Fregonara, P, Haissaguerre, M, Bordenave, L & Tabarin, A 2018, Journal of Nuclear Medicine, vol 59, no. 3, pp. 546-547. DOI: 10.2967/jnumed.117.202630